An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

Mohammad Haque; Xiaofang Xiong; Fengyang Lei; Jugal Kishore Das; Jianxun Song

doi:10.1016/j.xpro.2020.100264

An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

Mohammad Haque
, Xiaofang Xiong
, Fengyang Lei
, Jugal Kishore Das
, Jianxun Song

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

In T cell-based cancer immunotherapy, tumor antigen (Ag)-specific CD8⁺ cytotoxic T lymphocytes (CTLs) can specifically target tumor Ags on malignant cells. This promising approach drove us to adopt this strategy of T cell transfer (ACT)-based immunotherapy for chronic viral infections. Here, we describe the generation of hepatitis B virus (HBV) Ag-specific CTLs from induced pluripotent stem cells (iPSCs), i.e., iPSC-CTLs. Ag-specific iPSC-CTLs can target HBV Ag⁺ cells and infiltrate into the liver to suppress HBV replication in a murine model. For complete details on the use and execution of this protocol, please refer to Haque et al. (2020).

Original language	English (US)
Article number	100264
Journal	STAR Protocols
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/j.xpro.2020.100264
State	Published - Mar 19 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Biochemistry, Genetics and Molecular Biology
General Neuroscience
General Immunology and Microbiology
General Medicine

Access to Document

10.1016/j.xpro.2020.100264

Cite this

@article{ea77816b64184df7b09506b7fcc7ba32,

title = "An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells",

abstract = "In T cell-based cancer immunotherapy, tumor antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) can specifically target tumor Ags on malignant cells. This promising approach drove us to adopt this strategy of T cell transfer (ACT)-based immunotherapy for chronic viral infections. Here, we describe the generation of hepatitis B virus (HBV) Ag-specific CTLs from induced pluripotent stem cells (iPSCs), i.e., iPSC-CTLs. Ag-specific iPSC-CTLs can target HBV Ag+ cells and infiltrate into the liver to suppress HBV replication in a murine model. For complete details on the use and execution of this protocol, please refer to Haque et al. (2020).",

author = "Mohammad Haque and Xiaofang Xiong and Fengyang Lei and Das, \{Jugal Kishore\} and Jianxun Song",

note = "Funding Information: The authors thank Dr. Pei-Jer Chen from National Taiwan University Hospital for providing the pAAV/HBV1.2 construct and Dr. Adam J. Gehring from Toronto General Hospital Research Institute for providing the s183-specific TCR genes. This work was supported by the National Institutes of Health grants R01AI121180, R01CA221867, and R21AI128325 to J.S. J.S. designed the experiments, analyzed data, and contributed to the writing of the paper. M.H. F.L. and J.K.D. performed the experiments. X.X. and M.H. analyzed data. The authors declare no competing interests. Funding Information: The authors thank Dr. Pei-Jer Chen from National Taiwan University Hospital for providing the pAAV/HBV1.2 construct and Dr. Adam J. Gehring from Toronto General Hospital Research Institute for providing the s183-specific TCR genes. This work was supported by the National Institutes of Health grants R01AI121180 , R01CA221867 , and R21AI128325 to J.S. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2021",

month = mar,

day = "19",

doi = "10.1016/j.xpro.2020.100264",

language = "English (US)",

volume = "2",

journal = "STAR Protocols",

issn = "2666-1667",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

AU - Haque, Mohammad

AU - Xiong, Xiaofang

AU - Lei, Fengyang

AU - Das, Jugal Kishore

AU - Song, Jianxun

N1 - Funding Information: The authors thank Dr. Pei-Jer Chen from National Taiwan University Hospital for providing the pAAV/HBV1.2 construct and Dr. Adam J. Gehring from Toronto General Hospital Research Institute for providing the s183-specific TCR genes. This work was supported by the National Institutes of Health grants R01AI121180, R01CA221867, and R21AI128325 to J.S. J.S. designed the experiments, analyzed data, and contributed to the writing of the paper. M.H. F.L. and J.K.D. performed the experiments. X.X. and M.H. analyzed data. The authors declare no competing interests. Funding Information: The authors thank Dr. Pei-Jer Chen from National Taiwan University Hospital for providing the pAAV/HBV1.2 construct and Dr. Adam J. Gehring from Toronto General Hospital Research Institute for providing the s183-specific TCR genes. This work was supported by the National Institutes of Health grants R01AI121180 , R01CA221867 , and R21AI128325 to J.S. Publisher Copyright: © 2020 The Author(s)

PY - 2021/3/19

Y1 - 2021/3/19

N2 - In T cell-based cancer immunotherapy, tumor antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) can specifically target tumor Ags on malignant cells. This promising approach drove us to adopt this strategy of T cell transfer (ACT)-based immunotherapy for chronic viral infections. Here, we describe the generation of hepatitis B virus (HBV) Ag-specific CTLs from induced pluripotent stem cells (iPSCs), i.e., iPSC-CTLs. Ag-specific iPSC-CTLs can target HBV Ag+ cells and infiltrate into the liver to suppress HBV replication in a murine model. For complete details on the use and execution of this protocol, please refer to Haque et al. (2020).

AB - In T cell-based cancer immunotherapy, tumor antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) can specifically target tumor Ags on malignant cells. This promising approach drove us to adopt this strategy of T cell transfer (ACT)-based immunotherapy for chronic viral infections. Here, we describe the generation of hepatitis B virus (HBV) Ag-specific CTLs from induced pluripotent stem cells (iPSCs), i.e., iPSC-CTLs. Ag-specific iPSC-CTLs can target HBV Ag+ cells and infiltrate into the liver to suppress HBV replication in a murine model. For complete details on the use and execution of this protocol, please refer to Haque et al. (2020).

UR - https://www.scopus.com/pages/publications/85122801388

UR - https://www.scopus.com/pages/publications/85122801388#tab=citedBy

U2 - 10.1016/j.xpro.2020.100264

DO - 10.1016/j.xpro.2020.100264

M3 - Article

C2 - 33490980

AN - SCOPUS:85122801388

SN - 2666-1667

VL - 2

JO - STAR Protocols

JF - STAR Protocols

IS - 1

M1 - 100264

ER -

An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this